

December 16, 2016

Element Materials Technology 100 Frobisher Business Park Malvern Worcestershire WR14 1BX UK

## RE: Letter of Agency

To Whom It May Concern:

We certify that we are not subject to denial of federal benefits, which includes FCC benefits, pursuant to Section 5301 of the Anti-Drug Abuse ACT of 1988, U.S.C. 862. Further, no party, as defined in 47 CFR 1.2002(b), to the application, is subject to denial of federal benefits, that includes FCC benefits.

Should you need further information, please do not hesitate to contact me at (610) 727-6706 or via e-mail at samir.shah@tevapharm.com. Thank you for your attention to this matter.

Yours faithfully

Samir A. Shah, PhD

Jamis Shol

Senior Manager, Regulatory Affairs

Teva Pharmaceuticals